| Business Summary | | Advanced
Magnetics,
Inc.
develops,
manufactures
and
markets
organ-specific
contrast
agents
to
improve
the
diagnostic
capabilities
of
soft
tissue
magnetic
resonance
imaging
(MRI)
scans.
The
Company's
liver
contrast
agent,
Feridex
I.V.,
is
approved
and
marketed
in
Europe,
Japan,
the
United
States,
Argentina,
South
Korea,
China
and
Israel.
The
Company's
oral
contrast
agent,
GastroMARK,
used
for
delineating
the
bowel
in
MRI
procedures,
is
approved
and
marketed
in
Europe
and
the
United
States.
The
Company
has
received
an
approvable
letter,
subject
to
certain
conditions,
from
the
United
States
Food
and
Drug
Administration
for
Combidex,
the
Company's
contrast
agent
for
the
diagnosis
of
lymph
node
disease.
Code
7228,
the
Company's
lead
MRI
contrast
agent
in
the
development
pipeline,
is
currently
in
Phase
II
clinical
studies.
The
product
is
being
evaluated
for
MRI
applications
in
both
cardiology
and
oncology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Advanced
Magnetics,
Inc.
develops,
manufactures
and
markets
organ-specific
contrast
agents
to
improve
the
diagnostic
capabilities
of
soft
tissue
magnetic
resonance
imaging
(``MRI'')
scans.
For
the
nine
months
ended
6/30/01,
revenues
rose
64%
to
$4.4
million.
Net
income
before
acct.
change
totaled
$719
thousand
vs.
a
loss
of
$2.5
million.
Results
reflect
license
fee
revenues
from
a
license
and
marketing
arrangement
and
the
completion
of
certain
clinical
trials
for
Combidex. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jerome Goldstein, 61 Chairman,
CEO, Treasurer | $253K | -- | Leonard Baum, 47 Pres,
CEO | 239K | -- | James Matheson, 56 VP-Fin. | -- | -- | Paula Jacobs, Ph.D., 56 VP-Devel. | 138K | $3.6K | Dennis Lawler, 46 VP-Quality
Control | -- | -- | Dollar
amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|